Prospective Grant of Exclusive Patent License: Devices and Systems For Treating Valvular Regurgitation, 47757-47758 [2017-22157]
Download as PDF
<![CDATA[
47757
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Type of respondent
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total
burden hours
State Government .......................................................
Federal Government ....................................................
20
10
1
1
5/60
5/60
2
1
Total ......................................................................
250
250
........................
105
Dated: October 6, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
Dated: October 6, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–22156 Filed 10–12–17; 8:45 am]
[FR Doc. 2017–22141 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Devices and Systems For
Treating Valvular Regurgitation
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
NHLBI Special Emphasis Panel.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Single Site CLTR Review.
Date: November 6, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Chang Sook Kim, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7188, Bethesda, MD 20892–7924, 301–827–
7940, carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
VerDate Sep<11>2014
18:05 Oct 12, 2017
Jkt 244001
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an Exclusive
Patent License to Cook Medical
Technologies, LLC, located in
Bloomington, Indiana, to practice the
inventions embodied in the patent
applications listed in the
Supplementary Information section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
October 30, 2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Michael Shmilovich, Esq.,
Senior Licensing and Patent Manager,
31 Center Drive Room 4A29, MSC2479,
Bethesda, MD 20892–2479, phone
number 301–435–5019, or shmilovm@
mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Cook Medical
Technologies, LLC: NIH Ref. No. E–027–
2013/0 ‘‘Devices And Methods for
Treating Functional Triscupid Valve
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Regurgitation’’ U.S. Provisional Patent
Application 61/785,652 filed March 14,
2013, International Patent Application
PCT/US2014/025300 filed under the
Patent Cooperation Treaty on March 13,
2014, European Patent Application
14723540.2 having an international
filing date of March 13, 2014, and U.S.
Patent Application 14/776,488 also
having an international filing date of
March 13, 2014. NIH Ref. No. E–115–
2013/0 ‘‘Encircling Suture Delivery
System For Flexible Circumferential
Suture,’’ U.S. Provisional Patent
Application 61/834,357 filed June 12,
2013, International Patent Application
PCT/US2014/040716 filed under the
Patent Cooperation Treaty on June 3,
2014, European Patent Application
14735030.0 having an international
filing date of June 3, 2014 and U.S.
Patent Application 14/898,020 also
having an international filing date of
June 3, 2014. The patent rights in these
inventions have been assigned to the
Government of the United States of
America. The prospective exclusive
patent License territory may be
worldwide and a field of use limited to
valvular regurgitation.
The invention embodied in NIH Ref.
No. E–027–2013/0 relates to devices and
methods for treating functional
tricuspid valve regurgitation and related
conditions. The devices are adapted for
applying force to an area of a patient’s
heart along or near the atrioventricular
groove and can include a tensioning
element configured to be delivered by a
flexible member guided through a
catheter and positioned generally along
or near the atrioventricular groove, and
a compression member that can be
positioned along the tensioning element
and over a desired segment of the
atrioventricular groove to develop force
to be applied to an adjacent area of the
heart by selective tensioning of the
tensioning element.
The invention embodied in NIH Ref
No. E–115–2013/0 relates to devices for
delivering encircling implants that can
include two separate limbs held
together at a distal articulation by the
implant being delivered. The implant
can comprise a suture and/or a braided
E:\FR\FM\13OCN1.SGM
13OCN1
47758
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
tube. The implant can extend through or
over the limbs. The implant and at least
a distal portion of the limbs can be
compressible into a delivery shape that
allows for advancement through the
lumen of a delivery catheter. When the
distal portion of the limbs move out of
the delivery catheter, the limbs and
implant can resiliently assume a loop
shape that is complementary to a shape
of a target around which the encircling
implant is to be placed. The limbs are
then retracted from along the implant to
leave the implant in the desired delivery
position. The delivery device can be
used to place encircling implants
around the heart or other targets, and
the implant can be tightened to exert
compressive force on the target.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license
will be royalty bearing and may be
granted unless within fifteen (15) days
from the date of this published notice,
the NHLBI receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: September 22, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2017–22157 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
VerDate Sep<11>2014
18:05 Oct 12, 2017
Jkt 244001
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: AIDS and Related
Research Integrated Review Group; AIDSassociated Opportunistic Infections and
Cancer Study Section.
Date: November 6, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Washington, D.C.,
2401 M Street NW., Washington, DC 20037.
Contact Person: Eduardo A Montalvo,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7852, Bethesda, MD 20892, (301) 435–
1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; The BloodBrain Barrier, Neurovascular System and
CNS Therapeutics.
Date: November 7, 2017.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Linda MacArthur, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187,
Bethesda, MD 20892, 301–537–9986,
macarthurlh@csr.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group;
Behavioral and Social Consequences of HIV/
AIDS Study Section.
Date: November 8–9, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Admiral Fell Inn, 888 South
Broadway, Baltimore, MD 21231.
Contact Person: Mark P Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–806–
6596, rubertm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Decision Making and Aging in Alzheimer’s
Disease.
Date: November 8, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Kristin Kramer, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5205,
MSC 7846, Bethesda, MD 20892, (301) 437–
0911, kramerkm@csr.nih.gov.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Brain and Spinal Cord Injury.
Date: November 8, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Boris P Sokolov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217A,
MSC 7846, Bethesda, MD 20892, 301–408–
9115, bsokolov@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurovirology and Neurodevelopmental
Aspects of Zika Virus Infection.
Date: November 8, 2017.
Time: 2:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Wei-Qin Zhao, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181,
MSC 7846, Bethesda, MD 20892–7846, 301–
827–7238, zhaow@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Brain Disorders and Related
Neurosciences.
Date: November 9–10, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda Downtown,
7335 Wisconsin Ave, Bethesda, MD 20814.
Contact Person: Vilen A Movsesyan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040M,
MSC 7806, Bethesda, MD 20892, 301–402–
7278, movsesyanv@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–17–
094: Maximizing Investigators Research
Award (R35).
Date: November 9–10, 2017.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Dominique Lorang-Leins,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7766, Bethesda, MD 20892,
301.326.9721, Lorangd@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Immunobiology ExtremesAutoimmunity, Tolerance, and Cancer.
Date: November 9, 2017.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\13OCN1.SGM
13OCN1
]]>Agencies
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Pages 47757-47758]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22157]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Devices and
Systems For Treating Valvular Regurgitation
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung and Blood Institute (NHLBI), National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to Cook Medical
Technologies, LLC, located in Bloomington, Indiana, to practice the
inventions embodied in the patent applications listed in the
Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
October 30, 2017 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Michael Shmilovich, Esq., Senior Licensing and
Patent Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-
2479, phone number 301-435-5019, or shmilovm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to Cook
Medical Technologies, LLC: NIH Ref. No. E-027-2013/0 ``Devices And
Methods for Treating Functional Triscupid Valve Regurgitation'' U.S.
Provisional Patent Application 61/785,652 filed March 14, 2013,
International Patent Application PCT/US2014/025300 filed under the
Patent Cooperation Treaty on March 13, 2014, European Patent
Application 14723540.2 having an international filing date of March 13,
2014, and U.S. Patent Application 14/776,488 also having an
international filing date of March 13, 2014. NIH Ref. No. E-115-2013/0
``Encircling Suture Delivery System For Flexible Circumferential
Suture,'' U.S. Provisional Patent Application 61/834,357 filed June 12,
2013, International Patent Application PCT/US2014/040716 filed under
the Patent Cooperation Treaty on June 3, 2014, European Patent
Application 14735030.0 having an international filing date of June 3,
2014 and U.S. Patent Application 14/898,020 also having an
international filing date of June 3, 2014. The patent rights in these
inventions have been assigned to the Government of the United States of
America. The prospective exclusive patent License territory may be
worldwide and a field of use limited to valvular regurgitation.
The invention embodied in NIH Ref. No. E-027-2013/0 relates to
devices and methods for treating functional tricuspid valve
regurgitation and related conditions. The devices are adapted for
applying force to an area of a patient's heart along or near the
atrioventricular groove and can include a tensioning element configured
to be delivered by a flexible member guided through a catheter and
positioned generally along or near the atrioventricular groove, and a
compression member that can be positioned along the tensioning element
and over a desired segment of the atrioventricular groove to develop
force to be applied to an adjacent area of the heart by selective
tensioning of the tensioning element.
The invention embodied in NIH Ref No. E-115-2013/0 relates to
devices for delivering encircling implants that can include two
separate limbs held together at a distal articulation by the implant
being delivered. The implant can comprise a suture and/or a braided
[[Page 47758]]
tube. The implant can extend through or over the limbs. The implant and
at least a distal portion of the limbs can be compressible into a
delivery shape that allows for advancement through the lumen of a
delivery catheter. When the distal portion of the limbs move out of the
delivery catheter, the limbs and implant can resiliently assume a loop
shape that is complementary to a shape of a target around which the
encircling implant is to be placed. The limbs are then retracted from
along the implant to leave the implant in the desired delivery
position. The delivery device can be used to place encircling implants
around the heart or other targets, and the implant can be tightened to
exert compressive force on the target.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive patent license will be royalty
bearing and may be granted unless within fifteen (15) days from the
date of this published notice, the NHLBI receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: September 22, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-22157 Filed 10-12-17; 8:45 am]
BILLING CODE 4140-01-P
